The company employs machine learning to uncover disease mechanisms at the mRNA level and to identify therapeutic candidates.

Emergent said it is separately working on increasing the availability of its overdose reverser on site for businesses.

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaemia in infants with congenital hyperinsulinism ...

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...

City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...

As a major report highlights the challenges of a struggling NHS, the call for preventative care is growing in the UK.

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) ...